Polymorphisms in the xenobiotic transporter Multidrug Resistance 1 (MDR1) and interaction with meat intake in relation to risk of colorectal cancer in a Danish prospective case-cohort study

BMC Cancer

Volumn 9, Issue , 2009, Pages

  Andersen, Vibeke ^a   Østergaard, Mette ^a   Christensen, Jane ^b   Overvad, Kim ^c   Tjønneland, Anne ^b   Vogel, Ulla ^d,e  

^a VIBORG HOSPITAL   (Denmark)

^b INSTITUTE OF CANCER EPIDEMIOLOGY   (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d NATIONAL RESEARCH CENTRE FOR THE WORKING ENVIRONMENT   (Denmark)

^e TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; BREAST CANCER RESISTANCE PROTEIN; CYCLOOXYGENASE 2; CYTOSINE; GUANINE; MULTIDRUG RESISTANCE PROTEIN 1; NONSTEROID ANTIINFLAMMATORY AGENT; THYMINE; ABCB1 PROTEIN, HUMAN; GLYCOPROTEIN P;

3' UNTRANSLATED REGION; ADULT; ALLELE; ARTICLE; CANCER RISK; CASE STUDY; CIGARETTE SMOKING; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; DENMARK; DNA POLYMORPHISM; EXON; FEMALE; FOOD INTAKE; GENE INTERACTION; GENETIC VARIABILITY; HETEROZYGOTE; HIGH RISK POPULATION; HOMOZYGOTE; HUMAN; HUMAN CELL; INTRON; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; MEAT; PROMOTER REGION; PROSPECTIVE STUDY; RISK FACTOR; WILD TYPE; ADENOCARCINOMA; ANIMAL; CASE CONTROL STUDY; COLORECTAL TUMOR; DIET; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; MIDDLE AGED; SINGLE NUCLEOTIDE POLYMORPHISM;

ADENOCARCINOMA; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CASE-CONTROL STUDIES; COHORT STUDIES; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2; DENMARK; DIET; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HETEROZYGOTE; HUMANS; MALE; MEAT; MIDDLE AGED; P-GLYCOPROTEIN; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS;

EID: 73249122912     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-9-407     Document Type: Article

References (72)

1. Cotterchio M, Boucher BA, Manno M, Gallinger S, Okey AB, Harper PA. Red meat intake, doneness, polymorphisms in genes that encode carcinogen-metabolizing enzymes, and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 2008, 17:3098-3107. 10.1158/1055-9965.EPI-08-0341, 2751598, 18990750.
2. Sorensen M, Autrup H, Olsen A, Tjonneland A, Overvad K, Raaschou-Nielsen O. Prospective study of NAT1 and NAT2 polymorphisms, tobacco smoking and meat consumption and risk of colorectal cancer. Cancer Lett 2008, 266:186-193. 10.1016/j.canlet.2008.02.046, 18372103.
3. Andersen V, Agerstjerne L, Jensen D, Ostergaard M, Saebo M, Hamfjord J. The multidrug resistance 1 (MDR1) gene polymorphism G-rs3789243-A is not associated with disease susceptibility in Norwegian patients with colorectal adenoma and colorectal cancer; a case control study. BMC Med Genet 2009, 10:18. 10.1186/1471-2350-10-18, 2662819, 19250544.
4. Campa D, Pardini B, Naccarati A, Vodickova L, Novotny J, Forsti A. A gene-wide investigation on polymorphisms in the ABCG2/BRCP transporter and susceptibility to colorectal cancer. Mutat Res 2008, 645:56-60.
5. Albermann N, Schmitz-Winnenthal FH, Z'graggen K, Volk C, Hoffmann MM, Haefeli WE. Expression of the drug transporters MDR1/ABCB1, MRP1/ABCC1, MRP2/ABCC2, BCRP/ABCG2, and PXR in peripheral blood mononuclear cells and their relationship with the expression in intestine and liver. Biochem Pharmacol 2005, 70:949-958. 10.1016/j.bcp.2005.06.018, 16054595.
6. Leslie EM, Deeley RG, Cole SP. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol 2005, 204:216-237. 10.1016/j.taap.2004.10.012, 15845415.
7. Sarkadi B, Homolya L, Szakacs G, Varadi A. Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system. Physiol Rev 2006, 86:1179-1236. 10.1152/physrev.00037.2005, 17015488.
8. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 1999, 39:361-398. 10.1146/annurev.pharmtox.39.1.361, 10331089.
9. bu-Qare AW, Elmasry E, bou-Donia MB. A role for P-glycoprotein in environmental toxicology. J Toxicol Environ Health B Crit Rev 2003, 6:279-288. 10.1080/10937400306466, 12746142.
10. Ebert B, Seidel A, Lampen A. Identification of BCRP as transporter of benzo[a]pyrene conjugates metabolically formed in Caco-2 cells and its induction by Ah-receptor agonists. Carcinogenesis 2005, 26:1754-1763. 10.1093/carcin/bgi139, 15917307.
11. Enokizono J, Kusuhara H, Ose A, Schinkel AH, Sugiyama Y. Quantitative investigation of the role of breast cancer resistance protein (Bcrp/Abcg2) in limiting brain and testis penetration of xenobiotic compounds. Drug Metab Dispos 2008, 36:995-1002. 10.1124/dmd.107.019257, 18322075.
12. van Herwaarden AE, Wagenaar E, Karnekamp B, Merino G, Jonker JW, Schinkel AH. Breast cancer resistance protein (Bcrp1/Abcg2) reduces systemic exposure of the dietary carcinogens aflatoxin B1, IQ and Trp-P-1 but also mediates their secretion into breast milk. Carcinogenesis 2006, 27:123-130. 10.1093/carcin/bgi176, 16000399.
13. Mizutani T, Masuda M, Nakai E, Furumiya K, Togawa H, Nakamura Y. Genuine functions of P-glycoprotein (ABCB1). Curr Drug Metab 2008, 9:167-174. 10.2174/138920008783571756, 18288958.
14. Johnstone RW, Ruefli AA, Smyth MJ. Multiple physiological functions for multidrug transporter P-glycoprotein?. Trends Biochem Sci 2000, 25:1-6. 10.1016/S0968-0004(99)01493-0, 10637601.
15. Huxley RR, Ansary-Moghaddam A, Clifton P, Czernichow S, Parr CL, Woodward M. The impact of dietary and lifestyle risk factors on risk of colorectal cancer: a quantitative overview of the epidemiological evidence. Int J Cancer 2009, 125:171-180. 10.1002/ijc.24343, 19350627.
16. World Cancer Research Fund/American Institute for CancerResearch. , http://www.dietandcancerreport.org/
17. Santarelli RL, Pierre F, Corpet DE. Processed meat and colorectal cancer: a review of epidemiologic and experimental evidence. Nutr Cancer 2008, 60:131-144. 10.1080/01635580701684872, 2661797, 18444144.
18. Liang PS, Chen TY, Giovannucci E. Cigarette smoking and colorectal cancer incidence and mortality: systematic review and meta-analysis. Int J Cancer 2009, 124:2406-2415. 10.1002/ijc.24191, 19142968.
19. Tsoi KK, Pau CY, Wu WK, Chan FK, Griffiths S, Sung JJ. Cigarette smoking and the risk of colorectal cancer: a meta-analysis of prospective cohort studies. Clin Gastroenterol Hepatol 2009, 7:682-688. 10.1016/j.cgh.2009.02.016, 19245853.
20. Seitz M, Wirthmuller U, Moller B, Villiger PM. The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients. Rheumatology (Oxford) 2007, 46:93-96. 10.1093/rheumatology/kel175, 16720636.
21. Ieiri I, Takane H, Otsubo K. The MDR1 (ABCB1) gene polymorphism and its clinical implications. Clin Pharmacokinet 2004, 43:553-576. 10.2165/00003088-200443090-00001, 15217301.
22. Woodahl EL, Ho RJ. The role of MDR1 genetic polymorphisms in interindividual variability in P-glycoprotein expression and function. Curr Drug Metab 2004, 5:11-19. 10.2174/1389200043489108, 14965248.
23. Kroetz DL, Pauli-Magnus C, Hodges LM, Huang CC, Kawamoto M, Johns SJ. Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics 2003, 13:481-494. 10.1097/00008571-200308000-00006, 12893986.
24. Wang D, Johnson AD, Papp AC, Kroetz DL, Sadee W. Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet Genomics 2005, 15:693-704. 10.1097/01.fpc.0000178311.02878.83, 16141795.
25. Fung KL, Gottesman MM. A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function. Biochim Biophys Acta 2009, 1794:860-871.
26. Larsen UL, Hyldahl OL, Guldborg NC, Eriksen J, Jakobsen P, Ostergaard M. Human intestinal P-glycoprotein activity estimated by the model substrate digoxin. Scand J Clin Lab Invest 2007, 67:123-134. 10.1080/00365510600986084, 17365992.
27. Maeda K, Sugiyama Y. Impact of genetic polymorphisms of transporters on the pharmacokinetic, pharmacodynamic and toxicological properties of anionic drugs. Drug Metab Pharmacokinet 2008, 23:223-235. 10.2133/dmpk.23.223, 18762709.
28. Hoffmeyer S, Burk O, von RO, Arnold HP, Brockmoller J, Johne A. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000, 97:3473-3478. 10.1073/pnas.050585397, 16264, 10716719.
29. Ho GT, Soranzo N, Nimmo ER, Tenesa A, Goldstein DB, Satsangi J. ABCB1/MDR1 gene determines susceptibility and phenotype in ulcerative colitis: discrimination of critical variants using a gene-wide haplotype tagging approach. Hum Mol Genet 2006, 15:797-805. 10.1093/hmg/ddi494, 16434479.
30. Ostergaard M, Ernst A, Labouriau R, Dagiliene E, Krarup HB, Christensen M. Cyclooxygenase-2, multidrug resistance 1, and breast cancer resistance protein gene polymorphisms and inflammatory bowel disease in the Danish population. Scand J Gastroenterol 2009, 44:65-73. 10.1080/00365520802400826, 18819034.
31. Kurzawski M, Drozdzik M, Suchy J, Kurzawski G, Bialecka M, Gornik W. Polymorphism in the P-glycoprotein drug transporter MDR1 gene in colon cancer patients. Eur J Clin Pharmacol 2005, 61:389-394. 10.1007/s00228-005-0926-5, 15912392.
32. Bae SY, Choi SK, Kim KR, Park CS, Lee SK, Roh HK. Effects of genetic polymorphisms of MDR1, FMO3 and CYP1A2 on susceptibility to colorectal cancer in Koreans. Cancer Sci 2006, 97:774-779. 10.1111/j.1349-7006.2006.00241.x, 16800822.
33. Osswald E, Johne A, Laschinski G, rjomand-Nahad F, Malzahn U, Kirchheiner J. Association of MDR1 genotypes with susceptibility to colorectal cancer in older non-smokers. Eur J Clin Pharmacol 2007, 63:9-16. 10.1007/s00228-006-0225-9, 17146660.
34. Imai Y, Nakane M, Kage K, Tsukahara S, Ishikawa E, Tsuruo T. C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol Cancer Ther 2002, 1:611-616.
35. Urquhart BL, Ware JA, Tirona RG, Ho RH, Leake BF, Schwarz UI. Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe. Pharmacogenet Genomics 2008, 18:439-448. 10.1097/FPC.0b013e3282f974dc, 18408567.
36. Zamber CP, Lamba JK, Yasuda K, Farnum J, Thummel K, Schuetz JD. Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine. Pharmacogenetics 2003, 13:19-28. 10.1097/00008571-200301000-00004, 12544509.
37. Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med 2007, 356:2131-2142. 10.1056/NEJMoa067208, 17522398.
38. Fukata M, Chen A, Klepper A, Krishnareddy S, Vamadevan AS, Thomas LS. Cox-2 is regulated by Toll-like receptor-4 (TLR4) signaling: Role in proliferation and apoptosis in the intestine. Gastroenterology 2006, 131:862-877. 10.1053/j.gastro.2006.06.017, 2169292, 16952555.
39. Zhang X, Miao X, Tan W, Ning B, Liu Z, Hong Y. Identification of functional genetic variants in cyclooxygenase-2 and their association with risk of esophageal cancer. Gastroenterology 2005, 129:565-576.
40. Szczeklik W, Sanak M, Szczeklik A. Functional effects and gender association of COX-2 gene polymorphism G-765C in bronchial asthma. J Allergy Clin Immunol 2004, 114:248-253. 10.1016/j.jaci.2004.05.030, 15316498.
41. Sanak M, Szczeklik W, Szczeklik A. Association of COX-2 gene haplotypes with prostaglandins production in bronchial asthma. J Allergy Clin Immunol 2005, 116:221-223. 10.1016/j.jaci.2005.03.010, 15990799.
42. Tan W, Wu J, Zhang X, Guo Y, Liu J, Sun T. Associations of functional polymorphisms in cyclooxygenase-2 and platelet 12-lipoxygenase with risk of occurrence and advanced disease status of colorectal cancer. Carcinogenesis 2007, 28:1197-1201. 10.1093/carcin/bgl242, 17151091.
43. Flossmann E, Rothwell PM. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 2007, 369:1603-1613. 10.1016/S0140-6736(07)60747-8, 17499602.
44. Friis S, Poulsen AH, Sorensen HT, Tjonneland A, Overvad K, Vogel U. Aspirin and other non-steroidal anti-inflammatory drugs and risk of colorectal cancer: a Danish cohort study. Cancer Causes Control 2009, 20:731-740. 10.1007/s10552-008-9286-7, 19122977.
45. Paik JH, Ju JH, Lee JY, Boudreau MD, Hwang DH. Two opposing effects of non-steroidal anti-inflammatory drugs on the expression of the inducible cyclooxygenase. Mediation through different signaling pathways. J Biol Chem 2000, 275:28173-28179.
46. Hermann M, Krum H, Ruschitzka F. To the heart of the matter: coxibs, smoking, and cardiovascular risk. Circulation 2005, 112:941-945. 10.1161/CIRCULATIONAHA.105.567842, 16103251.
47. Moraitis D, Du B, De Lorenzo MS, Boyle JO, Weksler BB, Cohen EG. Levels of cyclooxygenase-2 are increased in the oral mucosa of smokers: evidence for the role of epidermal growth factor receptor and its ligands. Cancer Res 2005, 65:664-670.
48. Badawi AF, Habib SL, Mohammed MA, Abadi AA, Michael MS. Influence of cigarette smoking on prostaglandin synthesis and cyclooxygenase-2 gene expression in human urinary bladder cancer. Cancer Invest 2002, 20:651-656. 10.1081/CNV-120002490, 12197220.
49. Tjonneland A, Olsen A, Boll K, Stripp C, Christensen J, Engholm G. Study design, exposure variables, and socioeconomic determinants of participation in Diet, Cancer and Health: a population-based prospective cohort study of 57,053 men and women in Denmark. Scand J Public Health 2007, 35:432-441. 10.1080/14034940601047986, 17786808.
50. Foodcalc 1.3 Computer program. 1998, , http://www.ibt.ku.dk/jesper/foodcalc/
51. Prosky L, Asp NG, Furda I, DeVries JW, Schweizer TF, Harland BF. Determination of total dietary fiber in foods and food products: collaborative study. J Assoc Off Anal Chem 1985, 68:677-679.
52. Tjonneland A, Overvad K, Haraldsdottir J, Bang S, Ewertz M, Jensen OM. Validation of a semiquantitative food frequency questionnaire developed in Denmark. Int J Epidemiol 1991, 20:906-912. 10.1093/ije/20.4.906, 1800429.
53. Tjonneland A, Haraldsdottir J, Overvad K, Stripp C, Ewertz M, Jensen OM. Influence of individually estimated portion size data on the validity of a semiquantitative food frequency questionnaire. Int J Epidemiol 1992, 21:770-777. 10.1093/ije/21.4.770, 1521982.
54. Vogel U, Christensen J, Dybdahl M, Friis S, Hansen RD, Wallin H. Prospective study of interaction between alcohol, NSAID use and polymorphisms in genes involved in the inflammatory response in relation to risk of colorectal cancer. Mutat Res 2007, 624:88-100.
55. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988, 16:1215. 10.1093/nar/16.3.1215, 334765, 3344216.
56. Barlow WE, Ichikawa L, Rosner D, Izumi S. Analysis of case-cohort designs. J Clin Epidemiol 1999, 52:1165-1172. 10.1016/S0895-4356(99)00102-X, 10580779.
57. Barlow WE. Robust variance estimation for the case-cohort design. Biometrics 1994, 50:1064-1072. 10.2307/2533444, 7786988.
58. Johnsen NF, Christensen J, Thomsen BL, Olsen A, Loft S, Overvad K. Physical activity and risk of colon cancer in a cohort of Danish middle-aged men and women. Eur J Epidemiol 2006, 21:877-884. 10.1007/s10654-006-9076-z, 17160429.
59. Ziemann C, Schafer D, Rudell G, Kahl GF, Hirsch-Ernst KI. The cyclooxygenase system participates in functional mdr1b overexpression in primary rat hepatocyte cultures. Hepatology 2002, 35:579-588. 10.1053/jhep.2002.31778, 11870370.
60. Zatelli MC, Luchin A, Piccin D, Tagliati F, Bottoni A, Vignali C. Cyclooxygenase-2 inhibitors reverse chemoresistance phenotype in medullary thyroid carcinoma by a permeability glycoprotein-mediated mechanism. J Clin Endocrinol Metab 2005, 90:5754-5760. 10.1210/jc.2005-1362, 16091477.
61. Fantappie O, Solazzo M, Lasagna N, Platini F, Tessitore L, Mazzanti R. P-glycoprotein mediates celecoxib-induced apoptosis in multiple drug-resistant cell lines. Cancer Res 2007, 67:4915-4923. 10.1158/0008-5472.CAN-06-3952, 17510421.
62. Patel VA, Dunn MJ, Sorokin A. Regulation of MDR-1 (P-glycoprotein) by cyclooxygenase-2. J Biol Chem 2002, 277:38915-38920. 10.1074/jbc.M206855200, 12138126.
63. Dietrich CG, Geier A, Oude Elferink RP. ABC of oral bioavailability: transporters as gatekeepers in the gut. Gut 2003, 52:1788-1795. 10.1136/gut.52.12.1788, 1773875, 14633964.
64. Kury S, Buecher B, Robiou-du-Pont S, Scoul C, Colman H, Le NT. Low-penetrance alleles predisposing to sporadic colorectal cancers: a French case-controlled genetic association study. BMC Cancer 2008, 8:326. 10.1186/1471-2407-8-326, 2585099, 18992148.
65. Sansbury LB, Millikan RC, Schroeder JC, North KE, Moorman PG, Keku TO. COX-2 polymorphism, use of nonsteroidal anti-inflammatory drugs, and risk of colon cancer in African Americans (United States). Cancer Causes Control 2006, 17:257-266. 10.1007/s10552-005-0417-0, 16489533.
66. Goodman JE, Bowman ED, Chanock SJ, Alberg AJ, Harris CC. Arachidonate lipoxygenase (ALOX) and cyclooxygenase (COX) polymorphisms and colon cancer risk. Carcinogenesis 2004, 25:2467-2472. 10.1093/carcin/bgh260, 15308583.
67. Cox DG, Pontes C, Guino E, Navarro M, Osorio A, Canzian F. Polymorphisms in prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) and risk of colorectal cancer. Br J Cancer 2004, 91:339-343. 2409800, 15173859.
68. Ulrich CM, Whitton J, Yu JH, Sibert J, Sparks R, Potter JD. PTGS2 (COX-2) -765G > C promoter variant reduces risk of colorectal adenoma among nonusers of nonsteroidal anti-inflammatory drugs. Cancer Epidemiol Biomarkers Prev 2005, 14:616-619. 10.1158/1055-9965.EPI-04-0510, 15767339.
69. Gong Z, Bostick RM, Xie D, Hurley TG, Deng Z, Dixon DA. Genetic polymorphisms in the cyclooxygenase-1 and cyclooxygenase-2 genes and risk of colorectal adenoma. Int J Colorectal Dis 2009, 24:647-654. 10.1007/s00384-009-0656-8, 19205707.
70. Barry EL, Sansbury LB, Grau MV, Ali IU, Tsang S, Munroe DJ. Cyclooxygenase-2 Polymorphisms, Aspirin Treatment, and Risk for Colorectal Adenoma Recurrence--Data from a Randomized Clinical Trial. Cancer Epidemiol Biomarkers Prev 2009,
71. Mifflin RC, Saada JI, Di Mari JF, Valentich JD, Adegboyega PA, Powell DW. Aspirin-mediated COX-2 transcript stabilization via sustained p38 activation in human intestinal myofibroblasts. Mol Pharmacol 2004, 65:470-478. 10.1124/mol.65.2.470, 14742690.
72. Friis S, Poulsen AH, Sorensen HT, Tjonneland A, Overvad K, Vogel U. Aspirin and other non-steroidal anti-inflammatory drugs and risk of colorectal cancer: A Danish cohort study. Cancer Causes Control 2009,